The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial
Open accessAbstract
Background: Dietary fat has been suggested to determine the therapeutic effect of enteral diets in Crohn's disease. Aim: To assess the efficacy of two whole protein based diets with different fat compositions (n6 polyunsaturated fatty acids v monounsaturated fatty acids) in inducing clinical remission in active Crohn's disease compared with steroids. Methods: Sixty two patients with active Crohn's disease were randomised to receive, for not more than 4 weeks: (a) a polymeric enteral diet containing 35 g of lipids per 1000 kcal, high in oleate (79%) and low in linoleate (6.5%) (PEN1), (b) an identical enteral diet except for the type of fat which was high in linoleate (45%) and low in oleate (28%) (PEN2), or (c) oral prednisone (1 mg/kg/day). Diets were double blindly administered. The steroid group received a conventional ward diet. Treatment failure was considered when remission was not achieved at week 4. Clinical activity and biological and nutritional parameters were monitored. Independent predictors of remission were identified by stepwise logistic regression analysis. Results: Overall remission rates (by intention to treat) were 20% (4/20) for PEN1, 52% (12/23) for PEN2, and 79% (15/19) for steroids (overall p=0.001; p<0.0005 steroids v PEN1, and p=0.056 PEN2 v PEN1). After excluding those patients who were non-compliant during the first week (per protocol analysis), remission rates were 27%, 63%, and 79%, respectively (p=0.008, steroids and PEN2 v PEN1). After adjusting for confounding variables, PEN1 remained significantly associated with a poor response. Conclusion: The type of dietary fat may be of importance for the primary therapeutic effect of enteral nutrition in active Crohn's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Owen, R. W., Mier, W., Giacosa, A., Hull, W. E., Spiegelhalder, B., & Bartsch, H. (2000) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(00)00061-2 · Cited by 577
Cited by
The microbiome and inflammatory bowel disease
Glassner, K. L., Abraham, B. P., & Quigley, E. M. M. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.11.003 · Cited by 837
Insights into the Role of Erysipelotrichaceae in the Human Host
Kaakoush, N. O. (2015) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2015.00084 · Cited by 721
ESPEN guideline: Clinical nutrition in inflammatory bowel disease
Forbes, A., Escher, J., Hébuterne, X., Kłęk, S., Krznaric, Z., Schneider, S., Shamir, R., Stardelova, K., Wierdsma, N., Wiskin, A. E., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.12.027 · Cited by 625
RetractedThe IBD in EPIC Study Investigators (2009) · Gut · doi:10.1136/gut.2008.169078 · Cited by 389
Dietary guidance from the international organization for the study of inflammatory bowel diseases
Levine, A., Rhodes, J. M., Lindsay, J. O., Abreu, M. T., Kamm, M. A., Gibson, P. R., Gasche, C., Silverberg, M. S., Mahadevan, U., Boneh, R. S., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.046 · Cited by 297
Metadata
- Authors
- Gassull, M. A., Fernández-Bañares, F., Cabré, E., Papo, M., Giaffer, M. H., Sánchez-Lombraña, J. L., Richart, C., Malchow, H., González-Huix, F., & Esteve, M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2002-08
- Volume
- 51
- Issue
- 2
- Pages
- 164-168
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2023078961
- Cited by
- 190
- References
- 1
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. https://app.cochat.ai/papers/10.1136/gut.51.2.164
- The paper
- Gassull, M. A., Fernández-Bañares, F., Cabré, E., Papo, M., Giaffer, M. H., Sánchez-Lombraña, J. L., Richart, C., Malchow, H., González-Huix, F., & Esteve, M. (2002). Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut. https://doi.org/10.1136/gut.51.2.164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.